ARTICLE | Finance
SNIPR targets the microbiome
How SNIPR's CRISPR microbiome IP drew Lundbeckfonden Emerge, LSP for $50M A round
March 15, 2019 8:49 PM UTC
SNIPR's strong IP position in prokaryotic CRISPR drew investors to a $50 million venture round led by Lundbeckfonden Emerge and LSP, the biggest series A yet for a CRISPR antibiotics and autoimmune company.
Lundbeckfonden Emerge's Christian Elling told BioCentury the early stage investment firm seeded SNIPR Biome ApS with €3 million in 2017. “It was a rare moment of truly great science and great people, and in this case great potential IP.”...